ERBB2 and cancer: Several well-defined copy number alterations have been identified in cancer, such as ERBB2 in breast cancer [16], N-MYC in neuroblastoma [17, 18] and EGFR-1 in head and neck tumours and gliomas [19–21], which have prognostic as well as predictive implications.